孟德尔随机化研究未发现尿酸与帕金森病进展之间存在因果关系。
Mendelian Randomisation Finds No Causal Association between Urate and Parkinson's Disease Progression.
机构信息
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom.
出版信息
Mov Disord. 2021 Sep;36(9):2182-2187. doi: 10.1002/mds.28662. Epub 2021 May 31.
BACKGROUND
Parkinson's disease (PD) is a common neurodegenerative movement disorder. Observational studies suggest higher levels of plasma urate may protect against Parkinson's risk and progression; however, causality cannot be established.
OBJECTIVES
This study set out to determine whether there is a true causal association between urate levels and PD age at onset (AAO) and progression severity using recently released PD AAO and progression genome-wide association study (GWAS) data.
METHODS
A large two-sample Mendelian randomization design was employed, using genetic variants underlying urate levels and the latest GWAS data for PD outcomes.
RESULTS
This study found no causal association between urate levels and Parkinson's risk, AAO, or progression severity.
CONCLUSIONS
Our results predict increasing urate levels as a therapeutic strategy is unlikely to benefit PD patients. © 2021 International Parkinson and Movement Disorder Society.
背景
帕金森病（PD）是一种常见的神经退行性运动障碍。观察性研究表明，血浆尿酸水平较高可能有助于预防帕金森病的发病风险和进展；然而，因果关系尚无法确定。
目的
本研究旨在利用最近发布的帕金森病发病年龄（AAO）和进展全基因组关联研究（GWAS）数据，确定尿酸水平与 PD AAO 和进展严重程度之间是否存在真正的因果关联。
方法
采用了大型两样本孟德尔随机化设计，使用尿酸水平的遗传变异和 PD 结局的最新 GWAS 数据。
结果
本研究未发现尿酸水平与帕金森病风险、AAO 或进展严重程度之间存在因果关联。
结论
我们的研究结果预测，增加尿酸水平作为一种治疗策略不太可能使 PD 患者受益。 © 2021 国际帕金森病和运动障碍学会。
Zotero 插件